BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+1.1%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$101M
AUM Growth
+$101M
(-13%)
Cap. Flow
+$2.26M
Cap. Flow
% of AUM
2.25%
Top 10 Holdings %
Top 10 Hldgs %
56.77%
Holding
80
New
12
Increased
15
Reduced
13
Closed
9
Top Buys
| 1 |
KLA
KLAC
|
$14.2M |
| 2 |
Ovintiv
OVV
|
$2.1M |
| 3 |
NovoCure
NVCR
|
$1.25M |
| 4 |
Freeport-McMoran
FCX
|
$782K |
| 5 |
Structure Therapeutics
GPCR
|
$747K |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$16.7M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$1.63M |
| 3 |
United Therapeutics
UTHR
|
$934K |
| 4 |
Travere Therapeutics
TVTX
|
$518K |
| 5 |
Masimo
MASI
|
$505K |
Sector Composition
| 1 | Healthcare | 79.06% |
| 2 | Technology | 14.1% |
| 3 | Energy | 6.07% |
| 4 | Materials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $15M | 14.86% |
323,358
-361,834
| -53% | -$16.7M |
|
|
2
KLA
KLAC
$115B
| $14.2M | 14.1% |
+15,848
| New | +$14.2M |
|
3
Corcept Therapeutics
CORT
$7.35B
| $4.93M | 4.9% |
67,200
+1,200
| +2% | +$88.1K |
|
|
4
Ovintiv
OVV
$10.8B
| $4.09M | 4.06% |
107,500
+55,300
| +106% | +$2.1M |
|
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.05M | 4.02% |
187,800
-75,600
| -29% | -$1.63M |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $3.89M | 3.86% |
30,940
+700
| +2% | +$88K |
|
7
Phreesia
PHR
$1.88B
| $3.26M | 3.24% |
114,700
| – | – |
|
8
Prothena Corp
PRTA
$441M
| $2.74M | 2.72% |
451,019
+118,045
| +35% | +$717K |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $2.65M | 2.63% |
48,000
-2
| -0% | -$111 |
|
10
Stoke Therapeutics
STOK
$1.08B
| $2.38M | 2.37% |
210,000
-5
| -0% | -$57 |
|
11
Elutia
ELUT
$96.7M
| $2.29M | 2.28% |
1,159,059
-28,676
| -2% | -$56.8K |
|
12
Castle Biosciences
CSTL
$696M
| $2.26M | 2.24% |
110,600
+22,196
| +25% | +$453K |
|
13
QuidelOrtho
QDEL
$1.95B
| $2.09M | 2.08% |
72,548
+4,929
| +7% | +$142K |
|
14
EQT Corp
EQT
$32.4B
| $2.02M | 2.01% |
34,619
| – | – |
|
15
Harrow
HROW
$1.44B
| $1.83M | 1.82% |
60,000
-12,910
| -18% | -$394K |
|
|
16
NovoCure
NVCR
$1.38B
| $1.8M | 1.79% |
101,000
+70,000
| +226% | +$1.25M |
|
17
Axogen
AXGN
$743M
| $1.75M | 1.73% |
161,000
| – | – |
|
18
Biodesix
BDSX
$62.6M
| $1.62M | 1.61% |
5,736,113
| – | – |
|
|
19
Travere Therapeutics
TVTX
$1.56B
| $1.52M | 1.51% |
103,000
-35,000
| -25% | -$518K |
|
20
Foghorn Therapeutics
FHTX
$286M
| $1.46M | 1.45% |
310,930
| – | – |
|
21
Alkermes
ALKS
$4.78B
| $1.43M | 1.42% |
50,000
| – | – |
|
|
22
Masimo
MASI
$7.59B
| $1.39M | 1.38% |
8,280
-3,000
| -27% | -$505K |
|
23
uniQure
QURE
$896M
| $1.38M | 1.37% |
98,697
+10,000
| +11% | +$139K |
|
|
24
United Therapeutics
UTHR
$13.8B
| $1.22M | 1.21% |
4,250
-3,250
| -43% | -$934K |
|
25
DocGo
DCGO
$153M
| $1.2M | 1.19% |
764,062
-100,000
| -12% | -$157K |
|